secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000059478-23-000219
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance
--------------------------------------------------------------------

- Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).
- FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.
- Mounjaro led New Products with $1.00B revenue; Growth Products up 16% to $4.93B, led by Verzenio, Jardiance, Taltz.
- Pipeline progress: donanemab submitted to FDA/EMA for Alzheimer's; tirzepatide submitted for chronic weight management; mirikizumab approved in EU.
- Announced agreements to acquire DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio to expand autoimmune and cardiometabolic pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/0000059478-23-000219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/lly-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000059478-23-000219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer